Ares-backed LaserAway explores sale as medical aesthetics deal activity accelerates

LaserAway is exploring a potential sale that could value the Los Angeles-based medical spa chain at more than $2 billion, as private equity interest in medical aesthetics continues to intensify. The company is backed by Ares Management Corporation (NYSE: ARES), Seidler Equity Partners and its founders, and has hired Harris Williams to run an early-stage sale process. LaserAway operates 219 clinics as of May 2026, up from 74 locations in 2021, and generates about $150 million in annual EBITDA. Ares Management Corporation shares recently traded at $130.50, giving the alternative asset manager a market capitalization of about $29.24 billion, with the stock still below its 52-week high of $195.26.

Why is LaserAway attracting buyer interest as medical spa chains become bigger consumer healthcare platforms?

LaserAway is attracting buyer interest because medical aesthetics has moved from a niche luxury service into a larger consumer healthcare category with repeat demand, brand loyalty and clinic-level scalability. The company offers treatments including laser hair removal, tattoo removal, skin rejuvenation and injectables such as Botox, placing it at the intersection of dermatology, beauty, wellness and discretionary healthcare. That combination appeals to private equity because it is less dependent on insurance reimbursement than traditional healthcare services and more recurring than many consumer retail categories.

The reported valuation above $2 billion suggests investors are no longer treating med spas as small local beauty businesses. LaserAway’s scale matters. Expanding from 74 clinics in 2021 to 219 locations by May 2026 gives the company a national footprint that smaller med spa operators cannot easily replicate. In a fragmented sector, a platform with national brand awareness, operating systems, provider training and clinic rollout experience can command a premium if buyers believe expansion can continue.

The EBITDA figure is also central. A company generating about $150 million in annual EBITDA can support serious sponsor interest, especially if buyers believe margins can improve through procurement, centralized marketing, technology, pricing discipline and clinic density. Private equity investors tend to like services businesses where fixed playbooks can be applied across locations. Med spas offer that possibility, but only if clinical quality and regulatory compliance keep pace with growth.

The consumer backdrop helps too. Aesthetic treatments have benefited from social media visibility, growing acceptance of injectables, demand for minimally invasive procedures and a broader willingness among consumers to spend on appearance-related services. The awkward truth is that vanity is recurring revenue when managed carefully. Wall Street has noticed.

How does Ares Management’s backing shape the LaserAway investment story?

Ares Management Corporation’s involvement gives LaserAway institutional credibility and places the sale process within a broader private equity exit cycle. Ares Management Corporation invested in LaserAway in 2021, alongside Seidler Equity Partners and the company’s founders. Since then, the business has expanded rapidly, suggesting that the current process may be designed to crystallize value after a period of aggressive clinic growth.

For Ares Management Corporation, a successful sale would be a visible monetization event in a consumer healthcare category that has attracted significant sponsor attention. The firm has broader exposure across credit, private equity, real estate and infrastructure, so LaserAway is not thesis-changing at the listed parent level. However, a strong exit would support the argument that Ares Management Corporation can identify and scale healthcare-adjacent consumer platforms beyond traditional private credit and real assets.

Ares Management Corporation’s broader market position also matters. The firm reported record fundraising earlier this year, with assets under management rising 18% year over year to $644.3 billion and dry powder of $158.1 billion. That gives Ares Management Corporation significant capacity to invest, refinance and exit across private markets, and a LaserAway sale would sit inside that larger asset-management machine rather than as a one-off consumer bet.

The stock market will not value Ares Management Corporation solely around LaserAway. Ares Management Corporation shares recently traded at $130.50, with a 52-week range of $95.80 to $195.26. The stock remains well below its 52-week high, reflecting wider private-market sentiment, rate expectations and valuation pressure across alternative asset managers. Still, a successful LaserAway transaction could reinforce confidence in Ares Management Corporation’s ability to generate exits in sectors where consumer demand and healthcare-like service models overlap.

Why does the med spa sector appeal to private equity despite regulatory complexity?

The med spa sector appeals to private equity because it combines several traits sponsors like: fragmentation, recurring visits, premium pricing, brand-building potential and scope for operational standardization. Many aesthetic clinics remain founder-owned or regionally managed, which creates roll-up potential for larger platforms. A national chain can centralize marketing, training, procurement, scheduling, customer relationship management and compliance while expanding into new markets.

The demand profile is also attractive. Treatments such as injectables and laser services are often repeat-based. Customers may return for maintenance, follow-up treatments or additional procedures, creating lifetime value beyond a single appointment. That makes the model different from one-time retail purchases. If customer acquisition costs are well managed and retention is strong, the economics can become compelling.

The category also benefits from being largely cash-pay. Unlike many healthcare businesses, med spa services are typically paid directly by consumers rather than reimbursed through insurers. That reduces exposure to payer negotiations and reimbursement cuts. It also increases exposure to discretionary spending, which means the model can be pressured if consumer budgets tighten. Beauty may be resilient, but it is not immune to rent, groceries and credit-card bills.

The regulatory complexity is the trade-off. Medical aesthetics sits in a grey zone between beauty services and healthcare. Rules differ by state around who can perform procedures, supervise treatments, prescribe injectables and manage medical decision-making. Private equity buyers must ensure that expansion does not outrun clinical governance. A med spa platform can scale quickly. A compliance problem can scale even faster.

What makes LaserAway different from smaller med spa operators?

LaserAway’s main differentiator is scale. A 219-location footprint gives the company a national presence that many independent and regional med spa operators lack. Scale can support brand recognition, stronger marketing efficiency, vendor leverage, standardized treatment protocols and better data on customer behaviour. In a sector where trust matters, a recognizable brand can help reduce consumer hesitation.

The company’s growth history also gives buyers something to underwrite. Moving from 74 clinics in 2021 to 219 by May 2026 suggests that LaserAway has already tested its expansion model across multiple markets. That does not guarantee future success, but it gives potential acquirers evidence that the operating playbook has worked beyond a small founder-led footprint. Rollout discipline is valuable because clinic expansion can destroy value if new locations open faster than staff training, local demand and clinical oversight can support.

LaserAway also operates across multiple treatment categories rather than relying on a single service. Laser hair removal, tattoo removal, skin rejuvenation and injectables serve overlapping but distinct customer needs. That can improve cross-selling and reduce dependence on one procedure type. It also requires broader staff training and equipment investment, which increases operational complexity.

The brand’s positioning sits in a useful middle ground. It is more specialized than a general beauty salon and more consumer-friendly than a traditional medical clinic. That makes the company accessible to customers seeking aesthetic treatments without feeling they are entering a hospital environment. For investors, that positioning can be powerful if it supports both trust and repeat use.

How could a $2 billion sale reshape medical aesthetics consolidation?

A LaserAway transaction above $2 billion would likely become a valuation marker for the medical aesthetics sector. It would signal that large med spa platforms can attract serious capital at healthcare-services scale, not just consumer-retail valuations. That could encourage other platform owners, founders and sponsors to explore transactions, especially if they believe the market is rewarding clinic density and EBITDA growth.

The deal could also accelerate competition among private equity firms for other med spa chains, dermatology-adjacent platforms and aesthetic treatment providers. Recent years have already seen sponsor interest from firms such as General Atlantic, Stride Consumer Partners, Leonard Green & Partners and KKR in related businesses. A strong LaserAway process would reinforce the view that medical aesthetics is becoming one of the more attractive consumer healthcare roll-up categories.

Strategic buyers may also take interest, although the buyer universe is more complex. Large healthcare services companies may be cautious about discretionary aesthetics. Beauty and wellness companies may lack medical governance infrastructure. Private equity may therefore remain the most likely buyer group because sponsors can tolerate category nuance if the unit economics and growth profile are attractive.

The larger consolidation risk is quality control. As capital floods into med spas, the sector may professionalize, but it may also face pressure to grow too quickly. If buyers push aggressive clinic expansion, staffing shortages, inconsistent clinical standards or customer complaints could become sector-wide issues. Med spa M&A needs medical discipline, not just multiple expansion. The face, after all, is not a spreadsheet.

What are the biggest risks for buyers looking at LaserAway?

The first risk is valuation. A price above $2 billion on about $150 million in annual EBITDA implies a substantial multiple. That may be justified if buyers believe growth remains strong, margins are durable and clinic expansion has a long runway. It becomes harder to defend if consumer demand slows, competition increases or new clinic productivity weakens.

The second risk is regulatory exposure. Medical spa rules vary across states, and buyers must understand supervision requirements, treatment protocols, licensing, advertising standards and medical governance. A national chain must operate consistently while respecting local rules. That is not easy when the regulatory map looks like it was designed by 50 separate committees, because it was.

The third risk is labour and provider capacity. Laser and injectable services require trained practitioners, clinical oversight and customer trust. Rapid expansion can strain hiring, training and quality assurance. If staffing becomes difficult, growth could slow or service standards could weaken.

The fourth risk is consumer cyclicality. Aesthetic treatments can feel resilient because customers value appearance and self-care, but many services are discretionary. If the economy weakens or household budgets tighten, some customers may delay treatments, trade down or reduce frequency. The model’s resilience needs to be proven through cycles, not only in a strong consumer environment.

What happens next for LaserAway, Ares Management and potential buyers?

The next phase is likely to involve buyer outreach, management presentations and deeper diligence led by Harris Williams. Since the process is early-stage, there is no guarantee of a sale. Ares Management Corporation, Seidler Equity Partners and LaserAway’s founders may decide to sell the company, bring in a new minority investor, refinance the business, or wait for a stronger market if bids do not meet expectations.

Potential buyers will focus on clinic-level economics, same-store growth, customer retention, treatment mix, provider staffing, regulatory compliance, market white space and capital expenditure requirements. They will also examine whether LaserAway’s rapid expansion has created sustainable operating density or simply added locations ahead of proven demand. In clinic roll-ups, growth quality matters more than map coverage.

A successful sale could give Ares Management Corporation a strong exit and set a benchmark for the broader medical aesthetics category. A failed or delayed process would not necessarily damage LaserAway’s business, but it could suggest buyers are becoming more disciplined on med spa valuations. That would matter for other sponsor-backed aesthetic platforms considering exits.

For the medical aesthetics sector, LaserAway is a test case. If buyers pay more than $2 billion for a fast-growing med spa chain, it confirms that beauty-focused healthcare services have become institutional assets. If buyers hesitate, it may show that the sector’s growth story still needs stronger proof on regulation, retention and recession resilience. Either way, the sale process will be watched closely. Botox, lasers and private equity rarely make a quiet room.

Key takeaways on what LaserAway’s sale process means for Ares Management and medical aesthetics investors

• LaserAway is exploring a potential sale that could value the medical spa chain at more than $2 billion.
• The company is backed by Ares Management Corporation, Seidler Equity Partners and its founders.
• LaserAway has hired Harris Williams to run an early-stage sale process.
• The company operates 219 clinics as of May 2026, compared with 74 locations in 2021.
• LaserAway generates about $150 million in annual EBITDA, making it one of the more substantial platforms in the med spa market.
• The sale process highlights private equity’s continuing appetite for medical aesthetics, injectables, laser treatments and consumer healthcare services.
• Ares Management Corporation shares trade below their 52-week high, but a strong LaserAway exit would support its private equity monetization story.
• The main buyer risks are valuation, state-by-state regulation, clinical quality, staffing and discretionary consumer spending.
• A successful deal could set a valuation benchmark for other med spa chains and aesthetic dermatology platforms.
• The broader signal is that medical aesthetics is moving from fragmented local clinics toward institutional private equity platforms.